FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235- 0104						
Estimated average burden							
hours per	0.5						

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A		2. Date o Requiring (Month/D 08/01/2	Statement ay/Year)	3. Issuer Name and Ticker or Trading Symbol TherapeuticsMD, Inc. [TXMD]								
(Last) 951 YAMA	(First) (Mi	ddle) E 220			Relationship of Report Issuer (Check all applicable)		· · ·		5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Street) BOCA RATON (City)	FL 334 (State) (Zip	431	,		Director X Officer (give title below) Executive Vio	10% Owner Other (specify below) ce President		Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Inst 4)	r. Form: D (D) or Ir			. Nature of Indirect Beneficial Iwnership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 4)		É	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.		
			ate kercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	5)		
Restricted S	tock Units	01	/01/2023 ⁽¹⁾	(1)	Common Stock	1,000,000	0		D			
Restricted S	tock Units		(2)	(2)	Common Stock	310,500	0		D			
Non-Qualifi to buy)	ed Stock Option (right 03	3/30/2021 ⁽³⁾	03/30/2030	Common Stock	125,000	1.07		D			
Performance	e Stock Units		(4)	(4)	Common Stock	310,500	0 D					

Explanation of Responses:

- 1. Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on January 1, 2023.
- 2. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
- 3. Underlying shares vest as follows: (i) 41,667 shares on March 30, 2021, (ii) 41,666 shares on March 30, 2022 and (iii) 41,667 shares on March 30, 2023.
- 4. The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

/s/ Edward Borkowski 08/07/2020 ** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB